OCT China 2026: China becoming ‘centre of gravity’ in global clinical trial sector
China’s rapid growth in recent years has sent ripples across the pharmaceutical sector. The country has experienced significant growth over the …
Post
-
-
Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity
Syntis Bio has reported results from the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101, …
-
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia. ARO-DIMER-PA …
-
Trial run: FDA launches pilot for expedited INDs
The US Food and Drug Administration (FDA) is set to launch its expedited investigational new drug (IND) pilot as it …
-
Vera set up for full approval for Trutakna in IgAN with Phase III win
Vera Therapeutics looks well placed for full approval of Trutakna (atacicept-vymj) in primary IgA nephropathy (IgAN) after successful confirmatory data. In …
-
Agentic AI trust gap slowing healthcare provider adoption, survey reveals
A new survey from digital healthcare security specialist Imprivata has revealed that, while artificial intelligence (AI) is now becoming commonplace …
-
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine, …
-
BioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trial
BioNTech and OncoC4 have reported the initial median overall survival (OS) results from the PRESERVE-003 Phase III trial’s non-pivotal stage …
-
Taiho, Cullinan report improved PFS in Phase III NSCLC trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported results from the Phase III REZILIENT3 trial, showing that zipalertinib combined …
-
CTS China 2026: Building resilience for Chinese biotechs to go global
If Chinese biotechs hope to expand globally, they need to build greater resilience to navigate the differing regulatory and import …
-
AstraZeneca’s cancer pipeline posts two wins and a loss
It has been a mixed few days for AstraZeneca’s oncology pipeline, as two drugs in its lung cancer portfolio have …
-
J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
Johnson & Johnson’s (J&J's) Rybrevant (amivantamab-vmjw) plus chemotherapy has been linked to the longest median overall survival (OS) seen in …
-
Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its …
-
ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial
At the European Respiratory Society (ERS) Congress 2026, investigators from AstraZeneca and collaborating institutions presented the company's Phase IIb PRESTO …
-
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for …
